Item 208 | First Year - FY2023 | Second Year - FY2024 |
|---|---|---|
| Financial Assistance For Educational and General Services (11000) | $338,858,802 | $338,858,802 |
| Eminent Scholars (11001) | FY2023 $3,063,732 | FY2024 $3,063,732 |
| Sponsored Programs (11004) | FY2023 $335,795,070 | FY2024 $335,795,070 |
| Fund Sources: | ||
| General | FY2023 $21,512,500 | FY2024 $21,512,500 |
| Higher Education Operating | FY2023 $297,240,022 | FY2024 $297,240,022 |
| Debt Service | FY2023 $20,106,280 | FY2024 $20,106,280 |
Authority: Title 23.1, Chapter 23, Code of Virginia.
A. Out of this appropriation, $1,162,500 the first year and $1,162,500 the second year from the general fund and $6,600,000 the first year and $6,600,000 the second year from nongeneral funds are designated to build research capacity in the areas of biomedical engineering and regenerative medicine.
B. Out of this appropriation, $20,000,000 the first year and $20,000,000 the second year from the general fund is designated for the support of cancer research. Virginia Commonwealth University shall submit an annual report to the Governor and the Chairs of the House Appropriations and Senate Finance and Appropriations Committees on its use of state funds in cancer research.
C. Out of this appropriation, $350,000 the first year and $350,000 the second year from the general fund is designated to support the Parkinson's and Movement Disorders Center.
D. The Higher Education Operating fund source listed in this Item is considered to be a sum sufficient appropriation, which is an estimate of funding required by the university to cover sponsored program operations.